GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Brooks Laboratories Ltd

Brooks Laboratories Q2 FY27 Net Profit Rs. 6,998.82 Lakhs, includes exceptional gain

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 07 Nov 2026, 06:23 PM IST  ·  BSE ID: 351ed26a-5f66-486c-8a23-669e6ad60735
View Original BSE Filing (PDF)
💡
In Simple Terms
Brooks Laboratories reported strong Q2 profits due to selling part of its stake in a subsidiary for Rs. 7,470.00 Lakhs.
🤖 AI Summary
  • Board approved standalone and consolidated unaudited financial results for Q2 and H1 FY27.
  • Standalone Net Profit for Q2 FY27 was Rs. 6,998.82 Lakhs, driven by an exceptional gain.
  • Exceptional gain of Rs. 7,470.00 Lakhs recorded from partial divestment of Brooks Steriscience Limited.
  • Consolidated Net Profit for Q2 FY27 reached Rs. 6,761.00 Lakhs, reflecting the exceptional item.
  • Company's shareholding in Brooks Steriscience Limited reduced from 49.00% to 37.52%.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Standalone Net Profit (Q2 FY27)
Rs. 6,998.82 Lakhs
Consolidated Net Profit (Q2 FY27)
Rs. 6,761.00 Lakhs
Exceptional Items Income (Q2 FY27)
Rs. 7,470.00 Lakhs
Standalone Revenue from operations (Q2 FY27)
Rs. 1,924.79 Lakhs
Standalone Revenue from operations (Q2 FY26)
Rs. 2,345.07 Lakhs
Share of loss from Jointly controlled entities and associates (H1 FY27)
Rs. 558.37 Lakhs
🏢 How This Affects the Company
📈
Business Impact
The partial divestment in Brooks Steriscience Limited changes the company's equity stake in the investee company, reducing it from 49.00% to 37.52% while retaining significant influence.
💰
Financial Impact
The recognition of an exceptional gain of Rs. 7,470.00 Lakhs significantly boosted both standalone and consolidated net profits for Q2 and H1 FY27. This transaction generated Rs. 7,473.60 Lakhs in aggregate consideration.
⚠️
Risk Impact
The reduction in ownership of Brooks Steriscience Limited decreases direct exposure to its operational losses, although the company continues to account for the investment using the equity method.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, which was significantly enhanced by the exceptional gain of Rs. 7,470.00 Lakhs from divestment.
🔍
Management Signal
The partial divestment of Brooks Steriscience Limited indicates management's strategic decision to rebalance investments and monetize assets, while retaining significant influence.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — evaluate revenue performance without exceptional items.
Updates on Brooks Steriscience Limited performance and company's equity method accounting.
Further details on utilization of funds from the divestment proceeds.
MEDIUM RISK While profits are high due to an exceptional gain, underlying revenue growth is negative and a joint venture reports losses.
💡 Investor Takeaway
Brooks Laboratories reported Q2 FY27 standalone Net Profit of Rs. 6,998.82 Lakhs and consolidated Net Profit of Rs. 6,761.00 Lakhs, both primarily due to a Rs. 7,470.00 Lakhs exceptional gain from selling an 11.48% stake in Brooks Steriscience Limited, reducing ownership to 37.52%.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Net Profit of Rs. 6,998.82 Lakhs for Q2 FY27 due to an exceptional gain, significantly improving profitability.
  • Realized Rs. 7,473.60 Lakhs from the partial divestment of Brooks Steriscience Limited, strengthening financial position.

⚠️ Concerns

  • Standalone Revenue from operations decreased to Rs. 1,924.79 Lakhs in Q2 FY27 from Rs. 2,345.07 Lakhs in Q2 FY26.
  • The jointly controlled entity, Brooks Steriscience Limited, incurred a loss after tax of Rs. 1,166.04 Lakhs for H1 FY27.
📅 Company Track Record
Previous filings for Brooks Laboratories Ltd show Q2 FY27 Standalone Net Profit of Rs. 6,998.82 Lakhs was boosted by a Rs. 7,470.00 Lakhs exceptional gain.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Brooks Laboratories' standalone net profit for Q2 FY27?
Brooks Laboratories reported a standalone Net Profit of Rs. 6,998.82 Lakhs for the quarter ended September 30, 2026 (Q2 FY27).
What caused the significant profit increase for Brooks Laboratories in Q2 FY27?
The significant profit increase was primarily due to an exceptional item income of Rs. 7,470.00 Lakhs, recognized from the partial divestment of an equity stake in Brooks Steriscience Limited.
What was the revenue from operations for Brooks Laboratories in Q2 FY27?
The standalone Revenue from operations for Brooks Laboratories in Q2 FY27 was Rs. 1,924.79 Lakhs, compared to Rs. 2,345.07 Lakhs in Q2 FY26.
How did the divestment affect Brooks Laboratories' shareholding in Brooks Steriscience Limited?
The company partially divested its equity stake in Brooks Steriscience Limited, reducing its shareholding from 49.00% to 37.52%.
What was Brooks Laboratories' share of loss from its jointly controlled entity for H1 FY27?
Brooks Laboratories recognized a share of loss after tax amounting to Rs. 558.37 Lakhs from Brooks Steriscience Limited for the half year ended September 30, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.